Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes

Thomas F. Dejgaard, Nanna B. Johansen, Christian S. Frandsen, Ali Asmar, Lise Tarnow, Filip K. Knop, Sten Madsbad, Henrik U. Andersen

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    We investigated the short-term effect of adding liraglutide 1.8 mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ≥25 kg/m2) adult patients (age ≥18 years) with type 1 diabetes and HbA1c ≥ 8% (64 mmol/mol) were randomized to liraglutide 1.8 mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial. At baseline and after 24 weeks of treatment, 24-hour blood pressure and heart rate, pulse pressure, pulse wave velocity and carotid intima-media thickness were evaluated. Compared with placebo, liraglutide increased 24-hour heart rate by 4.6 beats per minute (BPM); P =.0015, daytime heart rate by 3.7; P =.0240 and night-time heart rate by 7.5 BPM; P <.001 after 24 weeks. Diastolic nocturnal blood pressure increased by 4 mm Hg; P =.0362 in the liraglutide group compared with placebo. In conclusion, in patients with long-standing type 1 diabetes, liraglutide as add-on to insulin increased heart rate and did not improve other cardiovascular risk factors after 24 weeks of treatment.

    OriginalsprogEngelsk
    Sider (fra-til)734-738
    Antal sider5
    TidsskriftDiabetes, Obesity and Metabolism
    Vol/bind19
    Udgave nummer5
    DOI
    StatusUdgivet - maj 2017

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes' indeholder.

    Citationsformater